Last reviewed · How we verify
Sasapyrine (SALSALATE)
Salsalate works by inhibiting the enzyme COX-1 and COX-2, which are responsible for producing prostaglandins.
Sasapyrine, also known as salsalate, is a small molecule drug in the salsalate class. It is used to treat osteoarthritis and rheumatoid arthritis. The current owner of salsalate is not specified, and its commercial status is unknown. Salsalate works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation. As a result, it helps to reduce pain and inflammation in the affected joints.
At a glance
| Generic name | SALSALATE |
|---|---|
| Drug class | salsalate |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | discontinued |
Mechanism of action
Think of prostaglandins like messengers that tell your body to feel pain and become inflamed. Salsalate blocks these messengers from being made, which helps to reduce pain and inflammation. This makes it easier to move and feel comfortable in your joints.
Approved indications
- Osteoarthritis
- Rheumatoid arthritis
Common side effects
- tinnitus
- nausea
- hearing impairment
- rash
- vertigo
- abdominal pain
- diarrhea
- G.I. bleeding
- anaphylactic shock
- angioedema
- bronchospasm
- decreased creatinine clearance
Drug interactions
- warfarin
Key clinical trials
- Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use (EARLY_PHASE1)
- Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy (PHASE1,PHASE2)
- Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction (PHASE2)
- Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia (EARLY_PHASE1)
- Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy (PHASE2,PHASE3)
- Salsalate in Patients Mild to Moderate Alzheimer's Disease (PHASE1)
- Endometriosis and Microvascular Dysfunction: Role of Inflammation (EARLY_PHASE1)
- Inflammation Inhibition in Prediabetic Humans (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sasapyrine CI brief — competitive landscape report
- Sasapyrine updates RSS · CI watch RSS